Maravai Lifesciences Holdings, Inc.
MRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001823239
No open-market purchases or sales by Maravai Lifesciences Holdings, Inc. insiders were filed in the last 90 days; 177 institutions reported holding it in 13F filings for Q2 2026, worth $875.5M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Maravai Lifesciences Holdings, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 206
- −15 vs. Q2 2023
- Shares held
- 134.9M
- +8.07M (+6.4%) vs. Q2 2023
- Total value
- $1.35B
- −$231.1M (−14.6%) vs. Q2 2023
- New holders
- 30
- 98 more added
- Sold out
- 45
- 55 more reduced
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MRVI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 177 | $875.5M |
| Q1 2026 | 158 | $343.7M |
| Q4 2025 | 159 | $420.9M |
| Q3 2025 | 160 | $375.1M |
| Q2 2025 | 150 | $312.6M |
| Q1 2025 | 185 | $283.8M |
| Q4 2024 | 186 | $769.2M |
| Q3 2024 | 217 | $1.20B |
| Q2 2024 | 206 | $1.06B |
| Q1 2024 | 210 | $1.18B |
| Q4 2023 | 223 | $883.7M |
| Q3 2023 | 206 | $1.35B |
| Q2 2023 | 222 | $1.58B |
| Q1 2023 | 221 | $1.79B |
| Q4 2022 | 213 | $1.81B |
| Q3 2022 | 202 | $3.33B |
| Q2 2022 | 216 | $3.73B |
| Q1 2022 | 235 | $4.51B |
| Q4 2021 | 229 | $5.36B |
| Q3 2021 | 229 | $6.27B |
| Q2 2021 | 196 | $4.77B |
| Q1 2021 | 144 | $3.51B |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Maravai Lifesciences Holdings, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 5,927,308 | $59.3M | 0.00% | +181,493+3.2% | Added |
| 12 West Capital Management LP | 6,463,111 | $64.6M | 5.85% | +3,101,275+92.2% | Added |
| Massachusetts Financial Services Co | 8,153,480 | $81.5M | 0.03% | −3,000,776−26.9% | Reduced |
| Vanguard Group Inc | 10,217,282 | $102.2M | 0.00% | −341,685−3.2% | Reduced |
| Thrivent Financial for Lutherans | 11,838,369 | $118.4M | 0.28% | +3,533,237+42.5% | Added |
| GTCR LLC | 21,681,033 | $216.8M | 13.15% | 00.0% | Unchanged |
| RTW Investments, LP | 0 | $0 | 0.00% | −1,532,685−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −650,296−100.0% | Sold out |
| Curi Capital | 0 | $0 | 0.00% | −566,417−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −460,111−100.0% | Sold out |
| Prosight Management, LP | 0 | $0 | 0.00% | −314,300−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −265,700−100.0% | Sold out |
| Roubaix Capital, LLC | 0 | $0 | 0.00% | −235,480−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −231,484−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −153,946−100.0% | Sold out |
| Candriam Luxembourg S.C.A. | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Brookfield Asset Management Inc. | 0 | $0 | 0.00% | −97,854−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −96,365−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −89,934−100.0% | Sold out |
| Old Mission Capital LLC | 0 | $0 | 0.00% | −63,112−100.0% | Sold out |
| Pentwater Capital Management LP | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Toroso Investments, LLC | 0 | $0 | 0.00% | −33,718−100.0% | Sold out |
| Allianz Asset Management GmbH | 0 | $0 | 0.00% | −33,079−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −26,732−100.0% | Sold out |
| Alps Advisors Inc | 0 | $0 | 0.00% | −21,665−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −21,362−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −17,958−100.0% | Sold out |
| Vident Investment Advisory, LLC | 0 | $0 | 0.00% | −17,389−100.0% | Sold out |
| CI Private Wealth, LLC | 0 | $0 | 0.00% | −17,050−100.0% | Sold out |
| Fifth Third Bancorp | 0 | $0 | 0.00% | −16,560−100.0% | Sold out |
| Cannon Global Investment Management, LLC | 0 | $0 | 0.00% | −15,800−100.0% | Sold out |
| Intech Investment Management LLC | 0 | $0 | 0.00% | −14,113−100.0% | Sold out |
| Teacher Retirement System of Texas | 0 | $0 | 0.00% | −13,382−100.0% | Sold out |
| New Vernon Capital Holdings II LLC | 0 | $0 | 0.00% | −13,160−100.0% | Sold out |
| Parallax Volatility Advisers, L.P. | 0 | $0 | 0.00% | −12,616−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −11,800−100.0% | Sold out |
| CAPROCK Group, Inc. | 0 | $0 | 0.00% | −10,338−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −10,089−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −6,755−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −6,618−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| Harbor Capital Advisors, Inc. | 0 | $0 | 0.00% | −3,807−100.0% | Sold out |
| Headlands Technologies LLC | 0 | $0 | 0.00% | −991−100.0% | Sold out |
| Huntington National Bank | 0 | $0 | 0.00% | −273−100.0% | Sold out |
| PEAK6 Investments LLC | 0 | $0 | 0.00% | −93−100.0% | Sold out |
| Denali Advisors LLC | 0 | $0 | 0.00% | −91−100.0% | Sold out |
| Glass Jacobson Investment Advisors llc | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| First Horizon Advisors, Inc. | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Bogart Wealth, LLC | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Baker Avenue Asset Management, LP | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Disciplined Investments, LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Pictet Asset Management SA | – | – | – | – | Not filed |